Illumina, Inc. (ILMN)
|Net Income (ttm)||630.00M|
|Trading Day||June 16|
|Day's Range||447.50 - 457.20|
|52-Week Range||260.42 - 555.77|
Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track?
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--The DNA Data Storage Alliance, an organization of more than 25 leading companies formed by Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASD...
It'll cover a lot of ground in the next 14 years.
These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential ap...
Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Dia...
SAN DIEGO--(BUSINESS WIRE)--Illumina and BeSolveRD will study the clinical utility and health economic impact of WGS of patients with intellectual disabilities.
MELBOURNE, Australia--(BUSINESS WIRE)--Illumina and Next Generation Genomic Co. announced launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, NGS-based approach to NIPT.
SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Heal...
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock?
Is (ILMN) Outperforming Other Medical Stocks This Year?
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
10x Genomics stock has fallen, despite announcing strong first-quarter numbers.
We have narrowed down our search to five S&P 500 stocks that have attained a 52-week high this year but are currently trading at a deep discount. These are: MAR, PHM, WY, GM and ILMN.
Several executives who earned their spurs at dominant genetics sequencing company Illumina Inc. ( ILMN , Financial) hold key management positions at a firm that is planning a $100 million initial public...
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of ...
SAN DIEGO--(BUSINESS WIRE)--Illumina appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
Despite a Q1 beat, Illumina has seen its share price decline over the last week (five trading sessions). The only negative from the earnings announcement was the margin contraction.
Twist Bioscience brings to mind another genomic revolution pioneer.
It just might be.
SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bank of America 2021 Healthcare Confe...
Illumina Files Action for Annulment of European Commission's Decision Asserting Jurisdiction to Review GRAIL Acquisition
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission's decisio...
Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.
Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
SAN DIEGO--(BUSINESS WIRE)--Illumina announced commitment of $60 million to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation.
Nearly everything went right for the genomic sequencing pioneer.
Illumina (ILMN) delivered earnings and revenue surprises of 38.97% and 0.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021. First quarter results reflect record revenue: R...
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.
Illumina, Kartos Therapeutics Team Up To Develop Companion Diagnostic For TP53-Haboring Cancer Indications
Illumina Inc (NASDAQ: ILMN) and privately-held Kartos Therapeutics have announced a partnership to develop a next-generation sequencing-based TP53 companion diagnostic. The diagnostic will be based on I...
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
SAN DIEGO--(BUSINESS WIRE)--Illumina and Kartos Therapeutics announce a new partnership to co-develop a TP53 CDx based on the TruSight™ Oncology 500 (TSO 500) assay.
Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blo...
SAN DIEGO--(BUSINESS WIRE)--Illumina disagrees with the European Commission's Directorate-General for Competition's decision to review Illumina's acquisition of GRAIL.
Sometimes the most carefully laid plans hit unforeseen snags.
The gene sequencing giant has a couple of key challenges going forward.
SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers
SINGAPORE--(BUSINESS WIRE)--Illumina Named One of Singapore's Best Employers
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.
The chances are certainly higher now that the deal won't happen.
The chief executive of life sciences company Illumina argued Thursday his company's deal to buy back GRAIL would lead to cheaper cancer tests rather than potentially pushing up prices as the government ...
The biotech was under pressure last month, but it's bouncing back in April.
The DNA sequencing company is gearing up to report a big beat later this month.
Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.
Illumina stock gapped up Tuesday after the company preannounced 26% revenue growth in the first quarter and boosted its full-year guidance. Analysts were split on the preannouncement.
The shares of Illumina Inc (NASDAQ:ILMN) are surging today, up 9.2% to trade at $420 at last check, after the company announced better-than-expected preliminary current-quarter and full-year guidance.
Illumina CEO Francis deSouza on first-quarter results, outlook and more
Illumina issued preliminary current-quarter and full-year guidance that exceeded current analyst estimates. The life sciences company said its projected results are being driven by record orders in its ...
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers i... [Read more...]
Diagnostics & Research
|IPO Date |
Jul 28, 2000
|Stock Exchange |
|Ticker Symbol |
In 2020, Illumina's revenue was $3.24 billion, a decrease of -8.58% compared to the previous year's $3.54 billion. Earnings were $656.00 million, a decrease of -34.53%.
According to 18 analysts, the average rating for Illumina stock is "Hold." The 12-month stock price forecast is 410.18, which is a decrease of -9.24% from the latest price.